JP2022554391A5 - - Google Patents

Info

Publication number
JP2022554391A5
JP2022554391A5 JP2022526330A JP2022526330A JP2022554391A5 JP 2022554391 A5 JP2022554391 A5 JP 2022554391A5 JP 2022526330 A JP2022526330 A JP 2022526330A JP 2022526330 A JP2022526330 A JP 2022526330A JP 2022554391 A5 JP2022554391 A5 JP 2022554391A5
Authority
JP
Japan
Prior art keywords
compound according
substituted
independently selected
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022526330A
Other languages
English (en)
Japanese (ja)
Other versions
JP7645256B2 (ja
JP2022554391A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059226 external-priority patent/WO2021092262A1/en
Publication of JP2022554391A publication Critical patent/JP2022554391A/ja
Publication of JP2022554391A5 publication Critical patent/JP2022554391A5/ja
Priority to JP2025032508A priority Critical patent/JP7827911B2/ja
Application granted granted Critical
Publication of JP7645256B2 publication Critical patent/JP7645256B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022526330A 2019-11-05 2020-11-05 MrgprX2アンタゴニストおよびその使用 Active JP7645256B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025032508A JP7827911B2 (ja) 2019-11-05 2025-03-03 MrgprX2アンタゴニストおよびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962931174P 2019-11-05 2019-11-05
US62/931,174 2019-11-05
US201962931627P 2019-11-06 2019-11-06
US62/931,627 2019-11-06
US202063046476P 2020-06-30 2020-06-30
US63/046,476 2020-06-30
PCT/US2020/059226 WO2021092262A1 (en) 2019-11-05 2020-11-05 Mrgprx2 antagonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025032508A Division JP7827911B2 (ja) 2019-11-05 2025-03-03 MrgprX2アンタゴニストおよびその使用

Publications (3)

Publication Number Publication Date
JP2022554391A JP2022554391A (ja) 2022-12-28
JP2022554391A5 true JP2022554391A5 (cg-RX-API-DMAC7.html) 2023-10-31
JP7645256B2 JP7645256B2 (ja) 2025-03-13

Family

ID=73654898

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022526330A Active JP7645256B2 (ja) 2019-11-05 2020-11-05 MrgprX2アンタゴニストおよびその使用
JP2025032508A Active JP7827911B2 (ja) 2019-11-05 2025-03-03 MrgprX2アンタゴニストおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025032508A Active JP7827911B2 (ja) 2019-11-05 2025-03-03 MrgprX2アンタゴニストおよびその使用

Country Status (8)

Country Link
US (1) US20230027929A1 (cg-RX-API-DMAC7.html)
EP (1) EP4054570A1 (cg-RX-API-DMAC7.html)
JP (2) JP7645256B2 (cg-RX-API-DMAC7.html)
CN (2) CN120698981A (cg-RX-API-DMAC7.html)
AU (1) AU2020378009A1 (cg-RX-API-DMAC7.html)
CA (1) CA3159628A1 (cg-RX-API-DMAC7.html)
IL (2) IL326957A (cg-RX-API-DMAC7.html)
WO (1) WO2021092262A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
US20230029266A1 (en) 2019-11-05 2023-01-26 Dermira, Inc. MrgprX2 Antagonists for the Treatment of Inflammatory Disorders
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
WO2022152852A1 (en) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonists of mrgx2
CN115925622B (zh) * 2023-02-10 2025-04-22 山西永津集团有限公司 一种3-氰基吡啶-2-基氨基甲酸叔丁酯的合成方法
WO2025002360A1 (zh) * 2023-06-30 2025-01-02 北京普祺医药科技股份有限公司 一种mrgprx2拮抗剂、药物组合物以及其用途
IL326496A (en) * 2023-08-17 2026-04-01 Sanofi Sa Pyridyl imidazoles, their preparation and their therapeutic application
US20250084063A1 (en) 2023-08-18 2025-03-13 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
US12630562B2 (en) 2024-08-07 2026-05-19 Arcus Biosciences, Inc. Piperidylurea compounds and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493555A (en) * 1966-03-23 1970-02-03 Nepera Chem Co Inc 3-phenylazo-2,6-pyridyl dicyclopropane-carboxamide
US4287207A (en) * 1979-03-31 1981-09-01 Taiho Pharmaceutical Company, Limited Pharmaceutical composition containing 1,3,5-substituted biuret compound
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
JP2531989B2 (ja) * 1988-09-14 1996-09-04 吉富製薬株式会社 ピリジン化合物
US5290943A (en) * 1991-02-21 1994-03-01 Ichikawa Gosei Chemical Co., Ltd. Method of producing 2-acyl amino 5-halogenopyridine compounds
JPH05201981A (ja) * 1991-08-06 1993-08-10 Ichikawa Gosei Kagaku Kk 2−アミノ−3−ニトロ−5−ハロゲノピリジン類の製造方法
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US20060004029A1 (en) * 2002-08-30 2006-01-05 Akihiko Tsuruoka Nitrogen-containing aromatic derivatives
WO2004069160A2 (en) * 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
BRPI0417687A (pt) * 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
CN1736989A (zh) * 2004-08-20 2006-02-22 中国科学院大连化学物理研究所 一种杂环菊酯类化合物及其在除草杀菌方面的应用
BRPI0619052A2 (pt) * 2005-11-28 2011-09-20 Hoffmann La Roche compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de diacilglicerol aciltransferase, e seu uso
AU2007230911A1 (en) * 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
WO2008063625A2 (en) * 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
AU2008309517B2 (en) * 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
WO2010094644A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2011074658A1 (ja) * 2009-12-18 2011-06-23 田辺三菱製薬株式会社 新規抗血小板薬
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
EA201201274A1 (ru) * 2010-03-10 2013-04-30 Инджениум Фармасьютиклз Гмбх Ингибиторы протеинкиназ
JP6112486B2 (ja) * 2010-04-27 2017-04-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
WO2012170931A2 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
FR2982261B1 (fr) * 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
TW201329067A (zh) * 2011-12-08 2013-07-16 Amgen Inc 作為gka活化劑之脲化合物
WO2014125426A1 (en) * 2013-02-15 2014-08-21 Aurigene Discovery Technologies Limited Trisubstituted heterocyclic derivatives as ror gamma modulators
US9758505B2 (en) * 2014-02-12 2017-09-12 Iteos Therapeutics 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
AR106679A1 (es) * 2015-11-13 2018-02-07 Basf Se Oxadiazoles sustituidos para combatir hongos fitopatógenos
CN105924387A (zh) * 2016-04-28 2016-09-07 西安交通大学 一种具有抗肿瘤活性的双芳基脲化合物及其制备方法和应用
WO2018114783A1 (en) * 2016-12-23 2018-06-28 Bayer Pharma Aktiengesellschaft Tetrazole containing compounds
EP3498694A1 (en) * 2017-12-12 2019-06-19 Medibiofarma, S.L. New benzamide derivatives as ppar-gamma modulators

Similar Documents

Publication Publication Date Title
JP2025148482A5 (cg-RX-API-DMAC7.html)
JP2022554392A5 (cg-RX-API-DMAC7.html)
JP7641388B2 (ja) 一連のピペリジン置換安息香酸系化合物及びその使用
JP2022554389A5 (cg-RX-API-DMAC7.html)
RU2240322C2 (ru) Производные нафтиридина и содержащая их фармацевтическая композиция
TWI751099B (zh) 作為激酶抑制劑之吡唑基脲,包含其之製藥組成物及其用途
EA003087B1 (ru) Производные аденозина
DK2959903T3 (en) Medicine for the treatment of eye disease
AU2008246798A1 (en) Salt of heterocycle-substituted pyridine derivative or crystal thereof
KR20230021083A (ko) 면역 조절제
JP2008509901A (ja) p38MAPキナーゼインヒビターとしてのトリアゾロピリジニルスルファニル誘導体
CN113660931A (zh) 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
CN111333648A (zh) 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
TW202237596A (zh) 作為Wee-1抑制劑的稠環化合物
WO2022012593A1 (zh) 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
CN110981876B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
JP2023503320A5 (cg-RX-API-DMAC7.html)
JP2008521775A (ja) 炎症性疾患治療用の置換プテリジン
RU2200737C2 (ru) Пиримидо[4,5-b]индолы и промежуточное соединение (варианты)
JP3057829B2 (ja) 3−(1,2−ベンズイソキサゾール−3−イル)−4−ピリジンアミンおよび誘導体
CN110753688A (zh) 用于治疗呼吸系统疾病的化合物
JP7539485B2 (ja) ピラゾール誘導体の肺線維症治療剤
JPH09504777A (ja) ロイコトリエンアンタゴニストとしてのキノリン誘導体
US5051430A (en) 3-(1H-indazol-3-yl)-4-pyridinamines
WO2020086625A1 (en) Vaccine adjuvant